Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) EBIT Margin (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed EBIT Margin for 11 consecutive years, with 12.35% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 1939.0% to 12.35% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.37% through Dec 2025, up 2328.0% year-over-year, with the annual reading at 8.37% for FY2025, 2328.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 12.35% at BeOne Medicines, up from 11.55% in the prior quarter.
  • The five-year high for EBIT Margin was 89.06% in Q4 2021, with the low at 316.58% in Q2 2021.
  • Average EBIT Margin over 5 years is 59.87%, with a median of 25.96% recorded in 2023.
  • The sharpest move saw EBIT Margin soared 72953bps in 2021, then plummeted -21235bps in 2022.
  • Over 5 years, EBIT Margin stood at 89.06% in 2021, then tumbled by -238bps to 123.29% in 2022, then soared by 51bps to 60.5% in 2023, then soared by 88bps to 7.04% in 2024, then soared by 275bps to 12.35% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 12.35%, 11.55%, and 6.68% for Q4 2025, Q3 2025, and Q2 2025 respectively.